Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-11-01
2005-11-01
Solola, Taofiq (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S411000, C514S319000, C548S359100
Reexamination Certificate
active
06960608
ABSTRACT:
Novel fused indazoles and indoles are disclosed. Also disclosed are methods for the lowering and controlling of normal or elevated intraocular pressure as well as a method for the treatment of glaucoma using compositions containing one or more of the compounds of the present invention.
REFERENCES:
patent: 4690931 (1987-09-01), Wick et al.
patent: 4985424 (1991-01-01), van Wijngaarden et al.
patent: 5151444 (1992-09-01), Ueno et al.
patent: 5296504 (1994-03-01), Stjernschantz et al.
patent: 5352708 (1994-10-01), Woodward et al.
patent: 5385928 (1995-01-01), Flaugh
patent: 5422368 (1995-06-01), Sternschantz et al.
patent: 5494928 (1996-02-01), Bös
patent: 5561150 (1996-10-01), Wichmann
patent: 5571833 (1996-11-01), Kruse et al.
patent: 5578612 (1996-11-01), Macor et al.
patent: 5646173 (1997-07-01), Bös et al.
patent: 5874477 (1999-02-01), McConnell et al.
patent: 5889052 (1999-03-01), Klimko et al.
patent: 5902815 (1999-05-01), Olney et al.
patent: 6548493 (2003-04-01), Robichaud et al.
patent: 6552017 (2003-04-01), Robichaud et al.
patent: 6713471 (2004-03-01), Robichaud et al.
patent: 2004/0034015 (2004-02-01), Robichaud et al.
patent: 718057 (1968-12-01), None
patent: 0771563 (1997-05-01), None
patent: WO 92/20338 (1992-11-01), None
patent: WO 94/13275 (1994-06-01), None
patent: WO 97/33579 (1997-09-01), None
patent: WO 98/18458 (1998-05-01), None
patent: WO 98/31354 (1998-07-01), None
patent: WO 98/56768 (1998-12-01), None
patent: WO 00/12475 (2000-03-01), None
patent: WO 00/12510 (2000-03-01), None
patent: WO 00/16761 (2000-03-01), None
patent: WO 00/35922 (2000-06-01), None
patent: WO 00/44753 (2000-08-01), None
Osborne, et al. “Do Beta-Adrenoceptors and Serotonin 5-HT1AReceptors Have Similar Functions in the Control of Intraocular Pressure in the Rabbit?”Ophthalmologica, vol. 210, pp. 308-314 (1996).
Wang, et al., “Effect of 5-methylurapidil, an α1a-adrenergic antagonist and 5-hydroxytryptamine1aagonist, on aqueous humor dynamics in monkeys and rabbits”Current Eye Research, vol. 16(8) pp. 769-775 (1997).
IOVS,Aqueous Humor Dynamics I, vol. 39(4), S488, 2236-B93 (1998).
Fiorella, “Role of 5-HT2Aand 5HT2creceptors in the stimulus effects of hallucinogenic drugs II: reassessment of LSD false positives,”Psychopharmacology, vol. 121:357-363, 1995.
Clark et al., “Heterocyclic Studies. Part 42. Pyrimido[5,4-d][1,2,3]triazines and some Related Tricyclic Compounds”J. Chem. Soc., Perkinsvol. 1, pp. 1475-1481 (1984).
Lown et al., “Formation of Novel 1,2-Oxathietanes from 2-Chloroethyl Sulfoxide Precursors and Their Reactions in Solution, Including Formal [σ2s+σ2a] Cycloreversions and Rearrangemetns”J. Amer. Chem. Soc., vol. 108, No. 13, pp. 3811-3818 (1986).
Benson, Jr. et al., “N-Alkyl-5,5-dimethyl-2-oxomorpholin-3-Y1 Radicals. Characterization and Reaction with Molecular Oxygen.”J. Amer. Chem. Soc.vol. 113, pp. 8879-8886 (1991).
Wentland et al., “Synthesis and Bacterial DNA Gyrase Inhibitory Properties of a Spirocyclopropylquinolone Derivative”J. Med. Chem., vol. 31, pp. 1694-1697 (1988).
Johnson, “Reaction of Aliphatic Amines with Formaldehyde and Nitroparaffins. II. Secondary Amines,”J. Amer. Chem. Soc., vol. 68, pp. 12-14 (1946).
Johnson et al., Binding to the Serotonin 5-HT2 Receptor by the Enantiomers of 125I-DOI,Neuropharmacology, vol. 26, pp. 1803-1806 (1987).
Bowen et al., “Nonlinear regression using spreadsheets,”Trends Pharmacol. Sci., vol. 16, pp. 413-417 (1995).
Trondlin, et al. “Der Mechanismus der Indazolsynthese aus o-Toluoldiazoniumsalzen2,” Chem. Ber., vol. 111, pp. 367-378 (1978).
Bos et al., “Novel Agonists of 5HT2c Receptors. Synthesis and Biological Evaluation of Substituted 2-(Indol-1-yl)-methylethylamines and 2-(Indenol[1,2-b]pyrrol-1-yl)-1-methylethylamines. Improved Therapeutics for Obsessive Compulsive Disorder,” J. Med. Chem., vol. 40, pp. 2762-2769 (1997).
Matlin, et al., “6-Diazopenicillanates. Part 1. Reactions with Furans,” J. Chem. Soc., Perkin Trans 1, pp. 89-96 (1990).
Griffin et al., “Pharmacological Characterization of an FP Prostaglandin Receptor on Rat Vascular Smoooth Muscle Cells (A7r5) Coupled to Phosphoinositide Turnover and Intracellular Calcuim Mobilization,” J. Pharmacol. Expt. Ther. vol. 286, No. 1, pp. 411-418 (1998).
Takahashi et al., “Synthesis of 2-Aryl-3-arylsufonylindoles and 2-Anilino-3-arylsulfonylindoles from 2-(Arylsufony)methylanilines Using the Aza-Wittig Reaction of Iminophosphoranes,” Synthesis, pp. 986-990 (1998).
Ruchardt et al., “Durchfuhrung der Jacobsonschen Indazolsynthese im Eintopfverfahren,” Liebigs Ann. Chem. pp. 908-927 (1980).
International Search Report for PCT/US02/17114 dated Aug. 23, 2002.
Dantanarayana Anura P.
May Jesse A.
Alcon Inc.
Kilyk & Bowersox P.L.L.C.
Shiao Robert
Solola Taofiq
LandOfFree
Fused indazoles and indoles and their use for the treatment... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Fused indazoles and indoles and their use for the treatment..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fused indazoles and indoles and their use for the treatment... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3505311